Epochs in the depressor/pressor balance of the renin-angiotensin system

Research output: Contribution to journalReview ArticleOtherpeer-review

11 Citations (Scopus)

Abstract

The renin–angiotensin system (RAS) plays a commanding role in the regulation of extracellular fluid homoeostasis. Tigerstadt and Bergman first identified the RAS more than two centuries ago. By the 1980s a voyage of research and discovery into the mechanisms and actions of this system led to the development of drugs that block the RAS, which have become the mainstay for the treatment of cardiovascular and renal disease. In the last 25 years new components of the RAS have come to light, including the angiotensin type 2 receptor (AT2R) and the angiotensin-converting enzyme 2 (ACE2)/angiotensin-(1–7) [Ang(1–7)]/Mas receptor (MasR) axis. These have been shown to counter the classical actions of angiotensin II (AngII) at the predominant angiotensin type 1 receptor (AT1R). Our studies, and those of others, have demonstrated that targeting these depressor RAS pathways may be therapeutically beneficial. It is apparent that the evolution of both the pressor and depressor RAS pathways is distinct throughout life and that the depressor/pressor balance of the RAS vary between the sexes. These temporal patterns of expression suggest that therapies targeting the RAS could be optimized for discrete epochs in life.
Original languageEnglish
Pages (from-to)761-771
Number of pages11
JournalClinical Science
Volume130
Issue number10
DOIs
Publication statusPublished - May 2016

Keywords

  • ageing
  • angiotensin receptors
  • cardiovascular disease
  • hypertension
  • sex differences

Cite this

@article{8c60f5c454ea4429956e987032eeac5e,
title = "Epochs in the depressor/pressor balance of the renin-angiotensin system",
abstract = "The renin–angiotensin system (RAS) plays a commanding role in the regulation of extracellular fluid homoeostasis. Tigerstadt and Bergman first identified the RAS more than two centuries ago. By the 1980s a voyage of research and discovery into the mechanisms and actions of this system led to the development of drugs that block the RAS, which have become the mainstay for the treatment of cardiovascular and renal disease. In the last 25 years new components of the RAS have come to light, including the angiotensin type 2 receptor (AT2R) and the angiotensin-converting enzyme 2 (ACE2)/angiotensin-(1–7) [Ang(1–7)]/Mas receptor (MasR) axis. These have been shown to counter the classical actions of angiotensin II (AngII) at the predominant angiotensin type 1 receptor (AT1R). Our studies, and those of others, have demonstrated that targeting these depressor RAS pathways may be therapeutically beneficial. It is apparent that the evolution of both the pressor and depressor RAS pathways is distinct throughout life and that the depressor/pressor balance of the RAS vary between the sexes. These temporal patterns of expression suggest that therapies targeting the RAS could be optimized for discrete epochs in life.",
keywords = "ageing, angiotensin receptors, cardiovascular disease, hypertension, sex differences",
author = "{Mirabito Colafella}, {Katrina M.} and Hilliard, {Lucinda M.} and Denton, {Kate M.}",
year = "2016",
month = "5",
doi = "10.1042/CS20150939",
language = "English",
volume = "130",
pages = "761--771",
journal = "Clinical Science and Molecular Medicine",
issn = "0009-9287",
publisher = "Portland Press",
number = "10",

}

Epochs in the depressor/pressor balance of the renin-angiotensin system. / Mirabito Colafella, Katrina M.; Hilliard, Lucinda M.; Denton, Kate M.

In: Clinical Science, Vol. 130, No. 10, 05.2016, p. 761-771.

Research output: Contribution to journalReview ArticleOtherpeer-review

TY - JOUR

T1 - Epochs in the depressor/pressor balance of the renin-angiotensin system

AU - Mirabito Colafella, Katrina M.

AU - Hilliard, Lucinda M.

AU - Denton, Kate M.

PY - 2016/5

Y1 - 2016/5

N2 - The renin–angiotensin system (RAS) plays a commanding role in the regulation of extracellular fluid homoeostasis. Tigerstadt and Bergman first identified the RAS more than two centuries ago. By the 1980s a voyage of research and discovery into the mechanisms and actions of this system led to the development of drugs that block the RAS, which have become the mainstay for the treatment of cardiovascular and renal disease. In the last 25 years new components of the RAS have come to light, including the angiotensin type 2 receptor (AT2R) and the angiotensin-converting enzyme 2 (ACE2)/angiotensin-(1–7) [Ang(1–7)]/Mas receptor (MasR) axis. These have been shown to counter the classical actions of angiotensin II (AngII) at the predominant angiotensin type 1 receptor (AT1R). Our studies, and those of others, have demonstrated that targeting these depressor RAS pathways may be therapeutically beneficial. It is apparent that the evolution of both the pressor and depressor RAS pathways is distinct throughout life and that the depressor/pressor balance of the RAS vary between the sexes. These temporal patterns of expression suggest that therapies targeting the RAS could be optimized for discrete epochs in life.

AB - The renin–angiotensin system (RAS) plays a commanding role in the regulation of extracellular fluid homoeostasis. Tigerstadt and Bergman first identified the RAS more than two centuries ago. By the 1980s a voyage of research and discovery into the mechanisms and actions of this system led to the development of drugs that block the RAS, which have become the mainstay for the treatment of cardiovascular and renal disease. In the last 25 years new components of the RAS have come to light, including the angiotensin type 2 receptor (AT2R) and the angiotensin-converting enzyme 2 (ACE2)/angiotensin-(1–7) [Ang(1–7)]/Mas receptor (MasR) axis. These have been shown to counter the classical actions of angiotensin II (AngII) at the predominant angiotensin type 1 receptor (AT1R). Our studies, and those of others, have demonstrated that targeting these depressor RAS pathways may be therapeutically beneficial. It is apparent that the evolution of both the pressor and depressor RAS pathways is distinct throughout life and that the depressor/pressor balance of the RAS vary between the sexes. These temporal patterns of expression suggest that therapies targeting the RAS could be optimized for discrete epochs in life.

KW - ageing

KW - angiotensin receptors

KW - cardiovascular disease

KW - hypertension

KW - sex differences

UR - http://www.ncbi.nlm.nih.gov/pubmed/27128801

U2 - 10.1042/CS20150939

DO - 10.1042/CS20150939

M3 - Review Article

VL - 130

SP - 761

EP - 771

JO - Clinical Science and Molecular Medicine

JF - Clinical Science and Molecular Medicine

SN - 0009-9287

IS - 10

ER -